AT EVERY STEP OF THE RESEARCH PROCESS FROM THE LAB TO THE CLINIC, WE ARE PURSUING INNOVATIVE WAYS TO PREVENT AND CONTROL CANCER.
New findings uncover an ancient mechanism that makes cancer cells invasive, explains melanoma’s resistance to therapy and opens the door to development of novel cancer therapies.
Chi Van Dang will join Ludwig as Scientific Director on July 1, 2017. A hematological oncologist and renowned researcher, Dang joins Ludwig from the University of Pennsylvania’s Abramson Cancer Center, which he has directed since 2011.
Scientists show how targeted drug can reverse the effects of certain immune cells that suppress responses to cancer immunotherapy. The drug they use in their studies is already in early-stage clinical trials.